Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Carcinomatous hemorrhagic–calcific metastatic encephalopathy following Osimertinib therapy

Carcinomatous hemorrhagic–calcific metastatic encephalopathy following Osimertinib therapy Acta Neurologica Belgica https://doi.org/10.1007/s13760-023-02286-y LE T TER TO  THE   EDITOR Carcinomatous hemorrhagic–calcific metastatic encephalopathy following Osimertinib therapy 1 2 Boby Varkey Maramattom  · Ranjini Ramachandran Nirmala Received: 6 March 2023 / Accepted: 5 May 2023 © The Author(s) under exclusive licence to Belgian Neurological Society 2023 The treatment of metastatic lung cancer has been revolu- encephalopathy following treatment with a third generation tionized by newer agentslike Tyrosine kinase inhibitors EGFR–TKI–Osimertinib [EGFR–TKI–O]. (TKIs). The use of 3rd generation TKIs, such as Osimerti- A 70-year-old man had been diagnosed with Exon 19 nib, has resulted in prolonged survival times. Even in cases mutation human epidermal growth factor receptor (EGFR) of advanced non-small cell lung cancer with CNS involve- positive adenocarcinoma [non-small cell lung cancer ment, Osimertinib has been shown todecrease the size and (NSCLC)], Stage IV1, 3 years earlier. He was treated with number of CNS lesions. However, patients can still expe- 4 cycles of pemetrexed and carboplatin, followed by Gef- rience disease progression despite Osimertinib treatment tinib for 18  months. Due to progressive disease, he was and ultimately succumb toparenchymal or leptomeningeal retreated with 2 cycles of Pemetrexed followed by Osimer- CNS metastases. Calcific miliary brain metastases, a rare tinib 10 months earlier. After 9 months of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neurologica Belgica Springer Journals

Carcinomatous hemorrhagic–calcific metastatic encephalopathy following Osimertinib therapy

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/carcinomatous-hemorrhagic-calcific-metastatic-encephalopathy-following-EBZAsx1J7T

References (9)

Publisher
Springer Journals
Copyright
Copyright © The Author(s) under exclusive licence to Belgian Neurological Society 2023
ISSN
0300-9009
eISSN
2240-2993
DOI
10.1007/s13760-023-02286-y
Publisher site
See Article on Publisher Site

Abstract

Acta Neurologica Belgica https://doi.org/10.1007/s13760-023-02286-y LE T TER TO  THE   EDITOR Carcinomatous hemorrhagic–calcific metastatic encephalopathy following Osimertinib therapy 1 2 Boby Varkey Maramattom  · Ranjini Ramachandran Nirmala Received: 6 March 2023 / Accepted: 5 May 2023 © The Author(s) under exclusive licence to Belgian Neurological Society 2023 The treatment of metastatic lung cancer has been revolu- encephalopathy following treatment with a third generation tionized by newer agentslike Tyrosine kinase inhibitors EGFR–TKI–Osimertinib [EGFR–TKI–O]. (TKIs). The use of 3rd generation TKIs, such as Osimerti- A 70-year-old man had been diagnosed with Exon 19 nib, has resulted in prolonged survival times. Even in cases mutation human epidermal growth factor receptor (EGFR) of advanced non-small cell lung cancer with CNS involve- positive adenocarcinoma [non-small cell lung cancer ment, Osimertinib has been shown todecrease the size and (NSCLC)], Stage IV1, 3 years earlier. He was treated with number of CNS lesions. However, patients can still expe- 4 cycles of pemetrexed and carboplatin, followed by Gef- rience disease progression despite Osimertinib treatment tinib for 18  months. Due to progressive disease, he was and ultimately succumb toparenchymal or leptomeningeal retreated with 2 cycles of Pemetrexed followed by Osimer- CNS metastases. Calcific miliary brain metastases, a rare tinib 10 months earlier. After 9 months of

Journal

Acta Neurologica Belgica – Springer Journals

Published: May 17, 2023

There are no references for this article.